US contribution continues to reduce owing to the pricing pressure in the base business and lower FTF launches. In FY17, TRP filed 17 ANDAs of which 6 were FTFs. Focus on filings in specialty segments like dermatology, oncology and ophthalmology will help sustain EBIDTA. About 5-6 pending launches and with 10-12 launches every year in FY18/19E we estimate US...